Theravance Biopharma Inc Dossier - Source-backed chat

Theravance Biopharma Inc

TBPHNASDAQ

SectorHealth Care

IndustryPharmaceuticals

Beta (adjusted)0.50

Intrinsic Value $9.87median of 5 methods · middle span $10-$17based on filings through 30 Jun 2026

Market Price $17.03Price as of 23 Sep 2026

OvervaluedIntrinsic value is 42% below the market price

−50% · IV below pricenear fair value ±15%IV above price · +50%

Data confidence Sign in to view data confidence

Market Cap $884.2M

Enterprise Value $664.4M

Shares Outstanding 52.3M diluted

Moat Rating None

Next Earnings Date5 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Theravance Biopharma (TBPH) has transitioned into a special situation play following the Phase 3 CYPRESS study failure for ampreloxetine in March 2026. The discontinuation of ampreloxetine removes the primary clinical growth catalyst, shifting the investment thesis to a capital return and asset monetization story. The downside is heavily protected by a robust cash balance of $394.7 million (with no debt), an expected $100.0 million milestone payment in 2026 tied to TRELEGY sales, and a highly profitable, patent-protected (until 2039) 35% profit share from YUPELRI sales. Activist pressure and an active Strategic Review Committee are expected to drive shareholder value through cost reductions (~60% operating expense cut) and potential monetization of the YUPELRI royalty stream.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets3 analysts · as of 18 Aug 2026

Low · most bearish analyst$17.00

Mean target$17.67

High · most bullish analyst$19.00

Street targets sit above today's price; our intrinsic value sits below it. Different horizons, different questions.

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$12.0020%

YUPELRI sales growth slows down significantly due to competitive pressures in the COPD market, or the wind-down of the R&D pipeline incurs higher-than-expected restructuring charges. The Strategic Review Committee fails to find a buyer for the royalty stream, leaving the company as a single-product entity with limited diversification.

Base CaseCentral scenario

$17.0050%

The company successfully executes its restructuring plan, winding down R&D to reduce operating expenses by 60% (~$70.0 million annualized savings) and generating $60.0 million to $70.0 million in annualized free cash flow from YUPELRI. The $100.0 million TRELEGY milestone is received in late 2026. The stock trades close to its net asset value, supported by ongoing share buybacks.

Bull CaseUpside scenario

$21.4030%

The Strategic Review Committee successfully orchestrates a sale of the YUPELRI royalty stream and the company's substantial Irish tax assets to a larger pharmaceutical buyer who can eliminate redundant SG&A costs. This, combined with the distribution of the $394.7 million cash balance and the incoming $100.0 million TRELEGY milestone, yields a total payout of $17.00 to $25.00 per share.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Strong downside protection with $394.7 million in cash and cash equivalents (as of Q1 2026) and no debt.
High visibility into a $100.0 million milestone payment in 2026, as 2025 TRELEGY sales of $3.91 billion already exceed the threshold required.
Stable, growing cash flows from YUPELRI (35% profit share) with settled patent litigation protecting the asset until 2039.
Aggressive cost-restructuring program expected to reduce operating expenses by 60% and generate $60.0 million to $70.0 million in annualized cash flow.

Key Investment Risks

Lack of pipeline diversification following the Phase 3 failure of ampreloxetine, leaving the company entirely dependent on YUPELRI.
Execution risk associated with winding down the R&D function and achieving the projected 60% cost savings.
Potential failure of the Strategic Review Committee to realize full value for the company's assets or execute a strategic sale.

Thesis Invalidation Triggers

Failure of GSK's TRELEGY sales to trigger the expected $100.0 million milestone payment in 2026.
A material decline in YUPELRI market share or net pricing in the US hospital and community channels.
Restructuring costs significantly exceeding the projected run-rate savings of $70.0 million.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.